A retrospective study of carboplatin and liposomal doxorubicin in patients with locally advanced or recurrent squamous cell carcinoma of the cervix.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e18021-e18021
Author(s):  
LEI Chang ◽  
Zhongfu Yuan ◽  
Wanjia Tian
Keyword(s):  
Cervical Cancer ◽  
Liposomal Doxorubicin ◽  
Overall Response Rate ◽  
Locally Advanced ◽  
Drug Efficacy ◽  
Efficacy And Safety ◽  
Recurrent Cervical Cancer ◽  
Starting Dose ◽  
Recurrent Squamous Cell Carcinoma ◽  
Duration Of Response

e18021 Background: The efficacy and safety of the combination of carboplatin and liposomal doxorubicin was tested in in patients with locally advanced or recurrent cervical cancer. Methods: The combination of carboplatin (area under the concentration curve AUC = 5) and liposomal doxorubicin (starting dose, 40 mg/m2) was administered intravenously every 28 days to 75 patients with locally advanced or recurrent cervical cancer to determine the drug efficacy and safety. Results: During the observation, all patients were received surgery or radiation before combination chemotherapy. 58 patients were assessable for response, and 12 patients were assessable for toxicity. During therapy, none patients required discontinuation of chemotherapy while only 2 patients needed dose reduction, because of side effect. The overall response rate was 77.3%, the median time to response was 8 weeks, the median duration of response was 24 weeks, and the median survival was 37 weeks. The most common adverse events with these patients included myelosuppression (69.0%), neutropenia (31.0%), anemia (23.0%), thrombocytopenia (21.0%) and neutropenic fever (11.0%). Conclusions: The combination of carboplatin and liposomal doxorubicin shows clinical efficacy and acceptable safety in patients with locally advanced or recurrent cervical carcinoma. It might provide a noval treatment for late stage cervical cancer.

SURGERY FOR RESIDUAL DISEASE AFTER RADIOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER

2019 ◽  
Vol 65 (5) ◽  
pp. 721-725
Author(s):  
Elmira Shakirova ◽  
Andrey Panov ◽  
Alevtina Akhmetzyanova ◽  
Aliya Gafiullina ◽  
L. Ibragimova ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Residual Disease ◽  
Locally Advanced ◽  
Residual Tumor ◽  
Advanced Cervical Cancer ◽  
Mri Imaging ◽  
Recurrent Cervical Cancer ◽  
Locally Advanced Cervical Cancer ◽  
Visible Effect ◽  
Adjuvant Hysterectomy

Aims: Chemoradiation (CRT) is the standard treatment for locally advanced cervical cancer (LACC). However part of the patients develop recurrence during the first year after treatment despite good visible effect at the first follow-up. The role of completion surgery after radiotherapy (RT) is still debated. A number of papers have showed that up to 60% of patients have residual tumor after CRT and RT. But such a surgery is not widely recommended because of increased morbidity of the treatment. The aim of this study was to assess the results of surgery after radiotherapy of LACC. Method: We retrospectively evaluated data on 86 patients with cervical cancer IB - IIIB stages (mostly stage IIB) who underwent surgery in different modalities after CRT and RT with good clinical response in our department in 2015-2018. Results: When small asymptomatic residual disease was detected early after radiotherapy radical hysterectomy was feasible in most of the cases. Patients with clinical manifestation of recurrence had very poor prognosis. Surgery of recurrent cervical cancer sufficiently deteriorates quality of life, even if possible. Conclusion: Thorough examination with adding MRI imaging after initial treatment of cervical cancer needed to identify patients who may benefit from adjuvant hysterectomy.

scholarly journals The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study

2019 ◽  
Vol Volume 13 ◽  
pp. 3419-3424 ◽  
Author(s):  
Jiangtao Yu ◽  
Ziwen Xu ◽  
Anyang Li ◽  
Jindi Zhang ◽  
Yi Wang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Retrospective Study ◽  
Efficacy And Safety ◽  
Recurrent Cervical Cancer

Capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: a retrospective study

2019 ◽  
Vol 29 (2) ◽  
pp. 272-276 ◽  
Author(s):  
Giuseppa Maltese ◽  
Stefano Lepori ◽  
Ilaria Sabatucci ◽  
Elisa Tripodi ◽  
Domenica Lorusso
Keyword(s):  
Cervical Cancer ◽  
Adverse Events ◽  
Cervical Carcinoma ◽  
Overall Response Rate ◽  
Response Rate ◽  
Gynecologic Oncology ◽  
Recurrent Cervical Cancer ◽  
Oral Capecitabine ◽  
Overall Response ◽  
Dismal Prognosis

BackgroundCervical cancer is a common malignancy among women and, when recurring, presents a dismal prognosis. After platinum failure, second-line treatments report response rates ranging from 3–15%, a median progression-free survival of about 3 months and a median overall survival of about 5.5 months.To retrospectively evaluate the activity and safety of capecitabine in patients with advanced/recurrent cervical carcinoma.MethodsA retrospective review of medical records of recurrent cervical cancer patients, who had failed a previous platinum–paclitaxel treatment and received oral capecitabine 1250 mg/m2 twice daily continuously from day 1 to day 14 every 21 days, was performed from December 2013 to March 2018 at the Gynecologic Oncology Unit of the Fondazione IRCCS National Cancer Institute of Milan, Italy. The response rate was evaluated every three cycles according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria. Common Terminology Criteria for Adverse Events version 4.0 were used to evaluate adverse events.ResultsWe retrospectively analyzed 35 patients with recurrent cervical carcinoma, treated with oral capecitabine. All patients had previously received and failed a combination of carboplatin plus paclitaxel as first-line therapy for advanced/recurrent disease. Median age at the first capecitabine administration was 53 years (range 27–82). All patients were evaluable for response: the overall response rate was 34.2% (2.8% complete responses and 31.4% partial responses) with a clinical benefit rate of 57% (overall response rate plus 22.8% stabilizations of disease). The most common grade 1–2 adverse events per patient were fatigue (71.3%), hand-foot syndrome (57.0%), diarrhea (31.3%), constipation (17.0%), and nausea (10.4%). Only three patients (8.5%) reported grade 3 adverse events.ConclusionsOur data suggest that oral capecitabine should be considered an active and safe treatment in patients with recurrent cervical carcinoma after platinum failure. Based on these results, we consider capecitabine as warranting further clinical evaluation.

Intraoperative Electron Beam Radiotherapy during Radical Surgery for Locally Advanced and Recurrent Cervical Cancer

2001 ◽  
Vol 82 (3) ◽  
pp. 538-543 ◽  
Author(s):  
R. Martı´nez-Monge ◽  
M. Jurado ◽  
J.J. Aristu ◽  
M. Moreno ◽  
M. Cambeiro ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Electron Beam ◽  
Radical Surgery ◽  
Locally Advanced ◽  
Recurrent Cervical Cancer ◽  
Electron Beam Radiotherapy

Weekly Carboplatin and Docetaxel for Locally Advanced Primary and Recurrent Cervical Cancer: A Phase I Study

2002 ◽  
Vol 87 (1) ◽  
pp. 98-103 ◽  
Author(s):  
D.T. Rein ◽  
C.M. Kurbacher ◽  
M. Breidenbach ◽  
T. Schöndorf ◽  
T. Schmidt ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase I ◽  
Phase I Study ◽  
Locally Advanced ◽  
Recurrent Cervical Cancer

Phase II Trial of Paclitaxel and Cisplatin in Metastatic and Recurrent Carcinoma of the Uterine Cervix

1999 ◽  
Vol 17 (3) ◽  
pp. 761-761 ◽  
Author(s):  
Christos A. Papadimitriou ◽  
Kyrillos Sarris ◽  
Lia A. Moulopoulos ◽  
George Fountzilas ◽  
Athanassios Anagnostopoulos ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Objective Response ◽  
Alternative Methods ◽  
Moderate Activity ◽  
Outpatient Basis ◽  
Recurrent Cervical Cancer ◽  
Two Agents ◽  
Duration Of Response ◽  
Cancer Of The Cervix ◽  
Grade 3

PURPOSE: Both paclitaxel and cisplatin have moderate activity in patients with metastatic or recurrent cancer of the cervix, and the combination of these two agents has shown activity and possible synergism in a variety of solid tumors. We administered this combination to patients with metastatic or recurrent cervical cancer to evaluate its activity. PATIENTS AND METHODS: Thirty-four consecutive patients were treated on an outpatient basis with paclitaxel 175 mg/m2 administered intravenously over a 3-hour period followed by cisplatin 75 mg/m2 administered intravenously with granulocyte colony-stimulating factor support. The chemotherapy was administered every 3 weeks for a maximum of six courses. RESULTS: Sixteen patients (47%; 95% confidence interval, 30% to 65%) achieved an objective response, including five complete responses and 11 partial responses. Responses occurred in 28% of patients with disease within the radiation field only and in 57% of patients with disease involving other sites. The median duration of response was 5.5 months, and the median times to progression and survival for all patients were 5 and 9 months, respectively. Grade 3 or 4 toxicities included anemia in 18% of patients and granulocytopenia in 15% of patients. Fifty-three percent of patients developed some degree of neurotoxicity; 21% of cases were grade 2 or worse. CONCLUSION: The combination of paclitaxel with cisplatin seems relatively well tolerated and moderately active in patients with metastatic or recurrent cervical cancer. The significant incidence of neurotoxicity is of concern, and alternative methods of administration of the two agents could be evaluated. Then, further study of this combination, alone or with the addition of other active agents, is warranted.

CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. TPS5597-TPS5597 ◽  
Author(s):  
Bradley J. Monk ◽  
Jyoti Mayadev ◽  
Ana T Nunes ◽  
Alicja Dabrowska Brown ◽  
Michelle Marcovitz ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Locally Advanced ◽  
Figo Stage ◽  
Stage Iii ◽  
Disease Stage ◽  
Advanced Cervical Cancer ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Locally Advanced Cervical Cancer ◽  
Eortc Qlq

TPS5597 Background: CCRT is the standard of care for locally advanced cervical cancer. CCRT with PD-1/PD-L1 pathway blockade may promote a more immunogenic environment through increased phagocytosis, cell death, and antigen presentation, leading to enhanced immune-mediated tumor surveillance. This Phase 3, randomized, multicenter, international, double-blind, placebo-controlled study is designed to determine the efficacy and safety of durvalumab with and following CCRT vs. CCRT alone in women with locally advanced cervical cancer (NCT03830866). Methods: The study will enroll immunotherapy-naïve adult patients (pts) with histologically confirmed cervical adenocarcinoma or cervical squamous or adenosquamous carcinoma (FIGO Stages IB2-IIB with node [N] positive and IIIA-IVA with any N) and no prior definitive surgical, radiation, or systemic therapy for cervical cancer. Approximately 714 pts will be randomized 1:1 to receive either durvalumab (1500 mg intravenously [IV]) or placebo every 4 weeks for 96 weeks. All pts will receive CCRT to the pelvis or pelvis + para-aortic radiotherapy field (45 Gy), followed by image-guided brachytherapy with cisplatin (40 mg/m2) IV or carboplatin (AUC2) IV once weekly for 5 weeks (6th dose optional). Randomization will be stratified by disease stage (FIGO Stage < III and N positive, FIGO Stage ≥III and N negative, or FIGO Stage ≥III and N positive) and region (US, Canada, EU, South Korea, and Japan vs. rest of the world). The primary endpoint is progression-free survival (assessed by investigator per RECIST v1.1 or histopathologic confirmation of local tumor progression). Secondary endpoints are overall survival, objective response and complete response (CR) rates, duration of response in pts with CR, incidence of local or distant disease progression or secondary malignancy, disease-related symptoms, and health-related quality of life (EORTC QLQ-C30 and EORTC QLQ-CX24). Pharmacokinetics, immunogenicity, and safety of durvalumab will also be assessed. Pt enrollment is ongoing. Clinical trial information: NCT03830866.

Sign in / Sign up

Export Citation Format

Share Document